Metabolic Dysfunction-Associated Steatohepatitis research hub
7 indexed studies · 3 currently recruiting
- recruitingTherapeutic exploratory (Phase II)
A Phase 2a Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of Efinopegdutide (MK-6024) in Adults with Compensated Cirrhosis Secondary to Metabolic Dysfunction-Associated Steatohepatitis
This study tests a new medicine called efinopegdutide for people with liver damage caused by fat buildup, known as MASH. Researchers want to see if the drug can safely reduce fat and scarring in the liver over 28 weeks compared to a dummy treatment with no active medicine.
Spain · France - authorisedTherapeutic confirmatory (Phase III)
A Phase 3, double-blind, randomized, placebo controlled, 2-arm study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis due to metabolic dysfunction-associated steatohepatitis (NEBULA-1)
This study tests a new injection called efimosfermin alfa for adults with compensated cirrhosis caused by MASH (severe fatty liver disease). Researchers want to see if the medicine can safely reduce liver scarring and prevent liver problems compared to a dummy treatment (placebo).
Netherlands · Greece · Austria - authorisedTherapeutic confirmatory (Phase III)
A Phase 3, two-part, double-blind, randomized, placebo-controlled study to investigate the safety and efficacy of efimosfermin alfa injection in adult participants with compensated cirrhosis (stage F4 fibrosis) due to metabolic dysfunction-associated steatohepatitis (NEBULA-2)
This study tests a new injection called efimosfermin alfa for adults with severe liver scarring caused by fatty liver disease (MASH). Researchers want to see if the medicine can reduce liver scarring and protect liver function compared to a dummy injection (placebo).
Netherlands · Germany · Austria - recruitingPHASE3
LIVERAGE™ - Cirrhosis: A Study to Test Whether Survodutide Helps People With a Liver Disease Called NASH/MASH Who Have Cirrhosis
This study looks at a new medicine called survodutide for adults with a liver condition called NASH or MASH and scarring (cirrhosis). Participants will get either the medicine or a dummy treatment, along with diet and exercise advice, to see if it helps their liver.
United States · Argentina · Australia - recruitingPHASE1, PHASE2
A Study to Evaluate ALN-CIDEB in Adult Participants With Metabolic Dysfunction-Associated Steatotic Liver Disease or With Metabolic Dysfunction-Associated Steatohepatitis (MASLD/MASH)
This study is testing a new drug called ALN-CIDEB for people with fatty liver conditions, MASLD and MASH. It aims to check how safe the drug is, if it causes side effects, and how it affects liver fat.
United States · United Kingdom - authorisedTherapeutic use (Phase IV)
Reducing Non-Alcoholic Steatohepatitis
This study is looking at how a medicine called Jardiance might help people with a liver condition called non-alcoholic steatohepatitis (NASH). Researchers want to see if it can improve liver health and reduce liver scarring, which is common in NASH.
Czechia - active not recruitingPHASE2
A Clinical Study of Efinopegdutide in People With Compensated Cirrhosis Due to Steatohepatitis (MK-6024-017)
This study is looking into a new medicine called efinopegdutide for a liver condition called MASH. We want to see if it can help reduce liver fat, swelling, and scarring in people with MASH and mild scarring. It also checks how safe the medicine is.
United States · Australia · Canada